Moderna

MRNA · NASDAQ

$242.08+$15.19 (+6.69%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $226.89

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The company is headquartered in Cambridge, Massachusetts and currently employs 4,700 full-time employees. The company went IPO on 2018-12-07. The company is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). The company also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. The company has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).

Employees: 4,700
Headquarters: Cambridge, Massachusetts
Listed: Dec 7, 2018
Sector: Health Care
Industry: Biotechnology
Website: modernatx.com

Leadership

Moderna executives
Name	Title	Since	Age
Noubar Afeyan	—	2010	62
Stephen Hoge	—	—	49
Stephane Bancel	—	2011	52
James Mock	—	—	48
Jerh Collins	—	—	59
Tracey Franklin	—	—	45
Rose Loughlin	—	—	41
Kate Cronin	—	—	58
Jacqueline Miller	—	—	53
Shannon Klinger	—	—	53
Sandra Horning	—	—	76
Abbas Hussain	—	—	60
Elizabeth Nabel	—	—	73
Francois Nader	—	—	68
David Rubenstein	—	—	75
Paul Sagan	—	—	66
Elizabeth Tallett	—	—	76

Revenue by product and region

Fiscal year ended Dec 31, 2025: $1.94B total revenue

By product

Net product sales$1.82B93.5%
Other revenue$126.00M6.5%

By region

United States$1.20B61.7%
Europe$53.00M2.7%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Moderna suppliers and customers
Company	Relationship	Country	Correlation
Catalent CTLT	Supplier and customer	US	0.86
Lonza Group LONN.SW	Supplier and customer	CH	0.81
Veeva Systems A VEEV	Supplier	US	0.80
Fusion Antibodies FAB.L	Supplier	GB	0.79
Takeda Pharmaceutical Company Limited TKPHF	Customer	—	0.75
AbCellera Biolog ABCL	Supplier and customer	CA	0.74
Alexandria Real Estate ARE	Supplier	US	0.47
Avacta Group AVCT.L	Supplier and customer	GB	0.41
Thermo Fisher Scientific TMO	Supplier and customer	US	0.14
Takeda Pharmaceutical	Supplier and customer	JP	0.12

Similar companies

Companies in the same industry as Moderna

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.